Last reviewed · How we verify
Influenza due to Influenza A virus — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Gocovri | AMANTADINE | Endo | Influenza A M2 Protein Inhibitor | Sigma non-opioid intracellular receptor 1 | 1968-01-01 | |
| GOCOVRI | GOCOVRI | Oregon Health and Science University | Influenza A M2 Protein Inhibitor | Sigma non-opioid intracellular receptor 1 | ||
| Amantadin | Amantadin | Centre Hospitalier Universitaire de Nice | Multidrug and toxin extrusion protein 1, Sigma non-opioid intracellular receptor 1, Glutamate [NMDA] receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Centre Hospitalier Universitaire de Nice · 1 drug in Influenza due to Influenza A virus
- Endo · 1 drug in Influenza due to Influenza A virus
- Oregon Health and Science University · 1 drug in Influenza due to Influenza A virus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Influenza due to Influenza A virus:
- Influenza due to Influenza A virus treatment updates — RSS
- Influenza due to Influenza A virus treatment updates — Atom
- Influenza due to Influenza A virus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Influenza due to Influenza A virus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/influenza-due-to-influenza-a-virus. Accessed 2026-06-10.
Related
- Influenza due to Influenza A virus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing